Skip to main content

Generic Corgard Availability

Last updated on Sep 6, 2023.

Corgard is a brand name of nadolol, approved by the FDA in the following formulation(s):

CORGARD (nadolol - tablet;oral)

  • Manufacturer: USWM
    Approved Prior to Jan 1, 1982
    Strength(s): 40MG [RLD] [AB], 80MG [RLD] [AB], 120MG (discontinued), 160MG (discontinued)
  • Manufacturer: USWM
    Approval date: October 28, 1986
    Strength(s): 20MG [RLD] [AB]

Has a generic version of Corgard been approved?

Yes. The following products are equivalent to Corgard:

nadolol tablet;oral

  • Manufacturer: ALEMBIC
    Approval date: June 2, 2023
    Strength(s): 20MG [AB], 40MG [AB], 80MG [AB]
  • Manufacturer: AMNEAL PHARMS CO
    Approval date: June 2, 2017
    Strength(s): 20MG [AB], 40MG [AB], 80MG [AB]
  • Manufacturer: AUROBINDO PHARMA
    Approval date: September 16, 2015
    Strength(s): 40MG [AB], 80MG [AB]
  • Manufacturer: AUROBINDO PHARMA
    Approval date: June 7, 2022
    Strength(s): 20MG [AB]
  • Manufacturer: BEXIMCO PHARMS USA
    Approval date: July 23, 2018
    Strength(s): 20MG [AB], 40MG [AB], 80MG [AB]
  • Manufacturer: CHARTWELL RX
    Approval date: October 5, 2017
    Strength(s): 20MG [AB], 40MG [AB], 80MG [AB]
  • Manufacturer: HERITAGE PHARMA
    Approval date: January 24, 1996
    Strength(s): 80MG [AB]
  • Manufacturer: HERITAGE PHARMA
    Approval date: August 30, 1996
    Strength(s): 20MG [AB], 40MG [AB]
  • Manufacturer: INVAGEN PHARMS
    Approval date: December 18, 2015
    Strength(s): 20MG [AB], 40MG [AB], 80MG [AB]
  • Manufacturer: RISING
    Approval date: October 31, 1993
    Strength(s): 20MG [AB], 40MG [AB], 80MG [AB]
  • Manufacturer: RK PHARMA
    Approval date: September 13, 2019
    Strength(s): 20MG [AB], 40MG [AB], 80MG [AB]
  • Manufacturer: SANDOZ
    Approval date: November 9, 1995
    Strength(s): 20MG [AB], 40MG [AB], 80MG [AB]
  • Manufacturer: ZYDUS PHARMS
    Approval date: July 28, 2017
    Strength(s): 20MG [AB], 40MG [AB], 80MG [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Corgard. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.


Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
AB Products meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (e.g. identical active ingredients, dosage form, and routes of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (e.g. AB1, AB2, AB7). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.